We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

113 hedge funds and large institutions have $262M invested in BioSpecifics Technologies Corp. in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 54 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

1% more funds holding

Funds holding: 112113 (+1)

1% less capital invested

Capital invested by funds: $264M → $262M (-$2.3M)

54% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 54

Holders
113
Holders Change
+1
Holders Change %
+0.89%
% of All Funds
2.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
25
Reduced
54
Closed
12
Calls
Puts
Net Calls
Net Calls Change

BSTC Hedge Fund Activity: Q1 2020 in Review

113 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q1 2020, worth a combined $262M — down 0.87% from $264M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BSTC positions and 12 closed out — a net gain of 3 holders — while 25 added to existing stakes and 54 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $15.6M. The largest seller was Allianz Asset Management, cutting an estimated $2.97M.

  • 113 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q1 2020, up from 112 in Q4 2019.
  • Funds reported $262M of BioSpecifics Technologies Corp. stock for Q1 2020, down 0.87% quarter-over-quarter.
  • 15 funds opened new BioSpecifics Technologies Corp. positions in Q1 2020 and 12 closed out, a net change of +3 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q1 2020 was Janus Henderson Group, an estimated $15.6M added.
  • The largest BioSpecifics Technologies Corp. seller in Q1 2020 was Allianz Asset Management, an estimated $2.97M sold.

Based on aggregated 13F filings for Q1 2020.